Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FQGX8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,868
Award facts
- Contract value 100% obligated
- $18,868.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $18,868.32 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta (a cystic fibrosis treatment medication). The delivery order, issued on December 15, 2025, with an ultimate completion date of December 16, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award represents a single delivery order issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to support recurring pharmaceutical and medical supply needs across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity demonstrating consistent performance across multiple therapeutic categories. The company's single-award IDC under PPV-G GEN V, valued at $499.999 billion with a completion date of December 31, 2036, authorizes the Defense Logistics Agency to issue delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. The contractor's established delivery order performance and broad product portfolio position it to fulfill the specialized pharmaceutical requirements of military healthcare operations globally throughout the contract period.
Quick answers
Who was awarded contract SPE2DR26FQGX8?
SPE2DR26FQGX8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FQGX8 worth?
The government has obligated $18,868 on SPE2DR26FQGX8.
Is contract SPE2DR26FQGX8 an order under another contract?
Yes. SPE2DR26FQGX8 is a delivery order under SPE2DR25D9156, an indefinite delivery contract.
Was contract SPE2DR26FQGX8 competed?
The extent of competition for SPE2DR26FQGX8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award